WuXi AppTec shares climbed sharply after the company forecast robust profit growth for 2025, citing rising demand for its drug development services. The Chinese CRDMO giant expects revenue to hit roughly 45.46 billion yuan, a year-on-year increase of about 15.8%. Adjusted net profit attributable to shareholders is projected to jump nearly 41%, while net profit excluding non-recurring items would rise 32.6%. Total net profit, boosted by gains from asset sales and business divestitures, is seen more than doubling.

Investors responded with an 8% surge in Shanghai-listed shares and a 10% rally in Hong Kong. The strong outlook reflects ongoing expansion in capacity and efficiency improvements across its integrated platform. WuXi AppTec has been a key player in helping global biotech firms accelerate drug discovery and manufacturing, benefiting from increased outsourcing trends in the pharmaceutical industry.

Its performance underscores growing investor confidence in China’s pharmaceutical services sector despite broader market uncertainties.